Platinum(IV) prodrugs multiply targeting genomic DNA, histone deacetylases and PARP-1

Add time:08/13/2019    Source:sciencedirect.com

Several Pt(IV) prodrugs containing SAA, a histone deacetylases inhibitor, were designed and prepared for multiply targeting genomic DNA, histone deacetylases and PARP-1. The resulting Pt(IV) prodrug had significantly strong antiproliferative activity against the tested cancer cell lines, especially SAA1, derived from the conjugation of cisplatin and SAA, had potent ability to overcome cisplatin resistance. Under the combined action of DNA platination and inhibition of HDACs and PARP-1 activity, the cytotoxic activity of SAA1 was 174-fold higher than cisplatin against cisplatin-resistant SGC7901/CDDP cancer cells. The mechanism of action of SAA1 was preliminarily investigated, in which cellular uptake, cell apoptosis and cell cycle arrest as well as western blot analysis were made by treating SAA1 with SGC7901/CDDP cells. Besides, HDACs inhibition activity and PARP-1 enzyme inhibition of SAA1 were also studied.

We also recommend Trading Suppliers and Manufacturers of POTASSIUM HEXACHLOROPLATINATE(IV) (cas 1307-80-8). Pls Click Website Link as below: cas 1307-80-8 suppliers

Prev:Reduction of hexachloroplatinate by ascorbic acid
Next:Textile-based RGO-muffled cobalt (II, III) oxide hybrid nano-architectures for flexible energy storage device)